Sreemoy Kanti Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sreemoy Kanti Das has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Liang Minghui
School of Pharmacy, Shangqiu Medical College, Shangqiu 476100, China
2 shared publications An Huichao
Lincoln University College Malaysia
1 shared publication- Arka Das
Department of Pharmaceutical Chemistry, Acharya and BM Reddy College of Pharmacy, Soldevanahalli, Bengaluru, 560107 Karnataka, India.
1 shared publication - Aziz Eftekhari
Department of Biochemistry, Faculty of Science, Ege University, 35040 Izmir, Turkey
1 shared publication - Jyotsna Pandit Khedkar
Department of Pharmacology, NES Gangamai College of Pharmacy, Nagaon, Dhule, Maharashtra, India
1 shared publication - Kalyan Kumar Sen
Department of Pharmaceutics, Gupta College of Technological Sciences, Asansol, West Bengal, India
1 shared publication
Latest Publications
- Open Access
- 2 June 2025
- Published by Academic Science Publications and Distributions in International Journal of Environmental Sciences
- p. 327-334
Mechanistic Insights Into The Inhibitory Effects Of Epigallocatechin Gallate (EGCG) From Green Tea Extract On Colon Cancer
Epigallocatechin gallate (EGCG), the primary active ingredient in green tea, possesses multiple biological activities including antioxidant, anti - inflammatory, and anti - tumor properties. This study investigated the inhibitory effect of EGCG on colon cancer and its potential mechanism via cell experiments.The results indicated that EGCG markedly inhibited the proliferation, invasion, and migration of colon cancer cells and induced cell apoptosis.This study offers a theoretical foundation for the application of EGCG as a preventive and therapeutic agent for colon cancer.
- 2 June 2025
- Published by Academic Science Publications and Distributions in International Journal of Environmental Sciences
- p. 327-334
Open AccessMechanistic Insights Into The Inhibitory Effects Of Epigallocatechin Gallate (EGCG) From Green Tea Extract On Colon Cancer
Epigallocatechin gallate (EGCG), the primary active ingredient in green tea, possesses multiple biological activities including antioxidant, anti - inflammatory, and anti - tumor properties. This study investigated the inhibitory effect of EGCG on colon cancer and its potential mechanism via cell experiments.The results indicated that EGCG markedly inhibited the proliferation, invasion, and migration of colon cancer cells and induced cell apoptosis.This study offers a theoretical foundation for the application of EGCG as a preventive and therapeutic agent for colon cancer.
- Open Access
- 10 May 2025
- Published by Academic Science Publications and Distributions in International Journal of Environmental Sciences
- Vol. 11 (4s) , 318-333
Evaluation of the Anti-Obesity Potential of Ginseng Flower Bud Extract
Background: Ginseng flower buds, a part of the ginseng plant, are known to be rich in ginsenosides, which are the active compounds attributed to ginseng's pharmacological effects. Although substantial scientific data have been accumulated regarding the pharmacological activities of ginseng roots, the therapeutic potential of ginseng flower buds has been largely overlooked. In this study, HepG2 cells treated with a free fatty acid mixture and hepatocytes isolated from rats fed a high-fat diet for three weeks were utilised as in vitro models of hepatic steatosis to evaluate the anti-steatotic effects of the extract1. Methods: The effects of ginseng flower buds were further investigated under pathologic conditions of hepatic steatosis induced by a high-fat diet over 12 weeks in C57BL/6J mice. A comprehensive analysis of hepatic gene expression profiles was conducted in mice treated with ginseng flower bud extract. Quantitative PCR was performed to validate the impact of the ginseng flower bud extract on the expression profiles of selected genes. Results: Treatment with ginseng flower bud extract significantly reduced the lipid droplets stained by Oil Red O and intracellular triglyceride levels in HepG2 cells and rat hepatocytes. In high-fat diet-fed mice, ginseng flower bud therapy (500 mg/kg) resulted in a marked reduction in histological signs of hepatic steatosis, with hepatic triglyceride levels reduced by 34.1% compared to the high-fat diet group2. These effects were accompanied by further improvements in insulin signalling. Global gene expression analysis revealed that ginseng flower bud treatment could reverse the hepatic gene expression profile associated with steatotic livers, with regulated genes involved in immune processes, insulin response, and lipid storage. Conclusion: The study provides strong evidence that ginseng flower buds may prevent or treat non-alcoholic fatty liver disease (NAFLD) by inhibiting hepatic inflammation and fatty acid uptake, and by enhancing hepatic insulin signalling pathways.
- 10 May 2025
- Published by Academic Science Publications and Distributions in International Journal of Environmental Sciences
- Vol. 11 (4s) , 318-333
Open AccessEvaluation of the Anti-Obesity Potential of Ginseng Flower Bud Extract
Background: Ginseng flower buds, a part of the ginseng plant, are known to be rich in ginsenosides, which are the active compounds attributed to ginseng's pharmacological effects. Although substantial scientific data have been accumulated regarding the pharmacological activities of ginseng roots, the therapeutic potential of ginseng flower buds has been largely overlooked. In this study, HepG2 cells treated with a free fatty acid mixture and hepatocytes isolated from rats fed a high-fat diet for three weeks were utilised as in vitro models of hepatic steatosis to evaluate the anti-steatotic effects of the extract1. Methods: The effects of ginseng flower buds were further investigated under pathologic conditions of hepatic steatosis induced by a high-fat diet over 12 weeks in C57BL/6J mice. A comprehensive analysis of hepatic gene expression profiles was conducted in mice treated with ginseng flower bud extract. Quantitative PCR was performed to validate the impact of the ginseng flower bud extract on the expression profiles of selected genes. Results: Treatment with ginseng flower bud extract significantly reduced the lipid droplets stained by Oil Red O and intracellular triglyceride levels in HepG2 cells and rat hepatocytes. In high-fat diet-fed mice, ginseng flower bud therapy (500 mg/kg) resulted in a marked reduction in histological signs of hepatic steatosis, with hepatic triglyceride levels reduced by 34.1% compared to the high-fat diet group2. These effects were accompanied by further improvements in insulin signalling. Global gene expression analysis revealed that ginseng flower bud treatment could reverse the hepatic gene expression profile associated with steatotic livers, with regulated genes involved in immune processes, insulin response, and lipid storage. Conclusion: The study provides strong evidence that ginseng flower buds may prevent or treat non-alcoholic fatty liver disease (NAFLD) by inhibiting hepatic inflammation and fatty acid uptake, and by enhancing hepatic insulin signalling pathways.
- Open Access
- 9 December 2024
- Published by Centivens Institute of Innovative Research
- Vol. 27 (5) , 730-735
A review of the research on the mechanism of EGCG targeting Foxo3 to inhibit the expression of Bnip3 and LC3 and alleviate autophagy to inhibit colon cancer
Colon cancer is a common malignant tumor, and its pathogenesis is complex and changeable. Studies have shown the potential therapeutic effect of epigallocatechin gallate (EGCG) on colon cancer, especially its inhibition of Bnip3 and LC3 expression by targeting the Foxo3 transcription factor, thereby mitigating the effect of autophagy inhibition on colon cancer cells. Autophagy is aberrantly activated in colon cancer and is associated with tumor growth and drug resistance. As a green tea extract with antitumor, antioxidant and anti-inflammatory functions, EGCG can regulate the expression of autophagy-related proteins and affect the growth and metastasis of cancer cells. Studies at home and abroad have shown that EGCG regulates autophagy by inhibiting Foxo3 activity, and has potential anti-tumor activity against colon cancer. However, the mechanism of action of EGCG in vivo is not well understood, and future studies need to further explore its role in animal models and clinical samples, as well as its effects on tumor cell metabolism, apoptosis, proliferation and metastasis, in order to provide a new strategy for the treatment of colon cancer. The purpose of this article is to provide systematic theoretical support for EGCG targeting Foxo3 to inhibit the expression of Bnip3 and LC3 and alleviate autophagy to inhibit colon cancer。
- 9 December 2024
- Published by Centivens Institute of Innovative Research
- Vol. 27 (5) , 730-735
Open AccessA review of the research on the mechanism of EGCG targeting Foxo3 to inhibit the expression of Bnip3 and LC3 and alleviate autophagy to inhibit colon cancer
Colon cancer is a common malignant tumor, and its pathogenesis is complex and changeable. Studies have shown the potential therapeutic effect of epigallocatechin gallate (EGCG) on colon cancer, especially its inhibition of Bnip3 and LC3 expression by targeting the Foxo3 transcription factor, thereby mitigating the effect of autophagy inhibition on colon cancer cells. Autophagy is aberrantly activated in colon cancer and is associated with tumor growth and drug resistance. As a green tea extract with antitumor, antioxidant and anti-inflammatory functions, EGCG can regulate the expression of autophagy-related proteins and affect the growth and metastasis of cancer cells. Studies at home and abroad have shown that EGCG regulates autophagy by inhibiting Foxo3 activity, and has potential anti-tumor activity against colon cancer. However, the mechanism of action of EGCG in vivo is not well understood, and future studies need to further explore its role in animal models and clinical samples, as well as its effects on tumor cell metabolism, apoptosis, proliferation and metastasis, in order to provide a new strategy for the treatment of colon cancer. The purpose of this article is to provide systematic theoretical support for EGCG targeting Foxo3 to inhibit the expression of Bnip3 and LC3 and alleviate autophagy to inhibit colon cancer。
- Open Access
- 8 September 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (8) , 39-49
Anti- COVID-19 drug discovery by flavonoid derivatives: an extensive computational drug design approach
The present study deals with the in-silico analyses of several flavonoid derivatives to explore COVID-19 through pharmacophore modelling, molecular docking, molecular dynamics, drug-likeness, and ADME properties. The initial literature study revealed that many flavonoids, including luteolin, quercetin, kaempferol, and baicalin may be useful against SARS β-coronaviruses, prompting the selection of their potential derivatives to investigate their abilities as inhibitors of COVID-19. The findings were streamlined using in silico molecular docking, which revealed promising energy-binding interactions between all flavonoid derivatives and the targeted protein. Notably, compounds 8, 9, 13, and 15 demonstrated higher potency against the coronavirus Mpro protein (PDB ID 6M2N). Compound 8 has a -7.2 Kcal/mol affinity for the protein and binds to it by hydrogen bonding with Gln192 and π-sulfur bonding with Met-165. Compound 9 exhibited a significant interaction with the main protease, demonstrating an affinity of -7.9 kcal/mol. Gln-192, Glu-189, Pro-168, and His-41 were the principle amino acid residues involved in this interaction. The docking score for compound 13 is -7.5 Kcal/mol, and it binds to the protease enzyme by making interactions with Leu-41, π-sigma, and Gln-189. These interactions include hydrogen bonding and π-sulfur. The major protease and compound 15 were found to bind with a favourable affinity of -6.8 Kcal/mol. This finding was further validated through molecular dynamic simulation for 1ns, analysing parameters such as RMSD, RMSF, and RoG profiles. The RoG values for all four of the compounds varied significantly (35.2–36.4). The results demonstrated the stability of the selected compounds during the simulation. After passing the stability testing, the compounds underwent screening for ADME and drug-likeness properties, fulfilling all the necessary criteria. The findings of the study may support further efforts for the discovery and development of safe drugs to treat COVID-19.
- 8 September 2024
- Published by CMB Association in Cellular and Molecular Biology
- Vol. 70 (8) , 39-49
Open AccessAnti- COVID-19 drug discovery by flavonoid derivatives: an extensive computational drug design approach
The present study deals with the in-silico analyses of several flavonoid derivatives to explore COVID-19 through pharmacophore modelling, molecular docking, molecular dynamics, drug-likeness, and ADME properties. The initial literature study revealed that many flavonoids, including luteolin, quercetin, kaempferol, and baicalin may be useful against SARS β-coronaviruses, prompting the selection of their potential derivatives to investigate their abilities as inhibitors of COVID-19. The findings were streamlined using in silico molecular docking, which revealed promising energy-binding interactions between all flavonoid derivatives and the targeted protein. Notably, compounds 8, 9, 13, and 15 demonstrated higher potency against the coronavirus Mpro protein (PDB ID 6M2N). Compound 8 has a -7.2 Kcal/mol affinity for the protein and binds to it by hydrogen bonding with Gln192 and π-sulfur bonding with Met-165. Compound 9 exhibited a significant interaction with the main protease, demonstrating an affinity of -7.9 kcal/mol. Gln-192, Glu-189, Pro-168, and His-41 were the principle amino acid residues involved in this interaction. The docking score for compound 13 is -7.5 Kcal/mol, and it binds to the protease enzyme by making interactions with Leu-41, π-sigma, and Gln-189. These interactions include hydrogen bonding and π-sulfur. The major protease and compound 15 were found to bind with a favourable affinity of -6.8 Kcal/mol. This finding was further validated through molecular dynamic simulation for 1ns, analysing parameters such as RMSD, RMSF, and RoG profiles. The RoG values for all four of the compounds varied significantly (35.2–36.4). The results demonstrated the stability of the selected compounds during the simulation. After passing the stability testing, the compounds underwent screening for ADME and drug-likeness properties, fulfilling all the necessary criteria. The findings of the study may support further efforts for the discovery and development of safe drugs to treat COVID-19.
- Open Access
- 1 January 2023
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2854 (1)
In an experimental animals, studying the impact of Bosentan on Sitagliptin’s anti-diabetic effect
Objective: The primary objective of the research undertaken was to appraise the impact of bosentan on the pharmacokinetic activity of anti-diabetic medicines in diabetic rats as well as normal rats. Methods: The animals under study both normal and diabetic were studied after receiving oral dosages of sitagliptin, bosentan along with combination of both, proper washout was maintained amid periods. At regular interval blood samples in series were taken through tail vain of rats, it was further subjected in analysis of glucose. To analyze glucose oxidase/peroxidase technique was used. Results: Level of blood glucose was found to be reduced with Sitagliptine in both diabetic and non-diabetic rats; Peak effect observed to last around 8 hours. Bosentan had a modest hypoglycemia effect on its own, but when combined with sitagliptin, it significantly reduced hypoglycemic activity in rats. According to the literature, Bosentan is a recognised inducer of Cytochrome P450 2C9 and 3A4 isozymes. As a result, Bosentan appears to influence the isozymes involved in sitagliptin metabolism (Cytochrome P450 3A4 and, to a lesser extent, CYP2C8), resulting in a reduced hypoglycemic activity. Conclusions: Although there was an interaction between the two medications, it did not appear to be of the pharmacodynamic kind and appeared to be of the pharmacokinetic type. When these medicines are taken together, however, blood glucose levels should be closely monitored.
- 1 January 2023
- Published by AIP Publishing in AIP Conference Proceedings
- Vol. 2854 (1)
Open AccessIn an experimental animals, studying the impact of Bosentan on Sitagliptin’s anti-diabetic effect
Objective: The primary objective of the research undertaken was to appraise the impact of bosentan on the pharmacokinetic activity of anti-diabetic medicines in diabetic rats as well as normal rats. Methods: The animals under study both normal and diabetic were studied after receiving oral dosages of sitagliptin, bosentan along with combination of both, proper washout was maintained amid periods. At regular interval blood samples in series were taken through tail vain of rats, it was further subjected in analysis of glucose. To analyze glucose oxidase/peroxidase technique was used. Results: Level of blood glucose was found to be reduced with Sitagliptine in both diabetic and non-diabetic rats; Peak effect observed to last around 8 hours. Bosentan had a modest hypoglycemia effect on its own, but when combined with sitagliptin, it significantly reduced hypoglycemic activity in rats. According to the literature, Bosentan is a recognised inducer of Cytochrome P450 2C9 and 3A4 isozymes. As a result, Bosentan appears to influence the isozymes involved in sitagliptin metabolism (Cytochrome P450 3A4 and, to a lesser extent, CYP2C8), resulting in a reduced hypoglycemic activity. Conclusions: Although there was an interaction between the two medications, it did not appear to be of the pharmacodynamic kind and appeared to be of the pharmacokinetic type. When these medicines are taken together, however, blood glucose levels should be closely monitored.